JFJun Fang

Jun Fang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jun Fang has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • DanQing Hu

    Department of Cardiology, Fujian Medical University Union Hospital; Fujian Cardiovascular Medicine Center; Fujian Institute of Coronary Artery Disease; Fujian Cardiovascular Research Center; Fujian Medical University Heart Center, 350001 Fuzhou, Fujian, China

    4 shared publications
  • TingXiang Lan

    Department of Cardiology, Fujian Medical University Union Hospital; Fujian Cardiovascular Medicine Center; Fujian Institute of Coronary Artery Disease; Fujian Cardiovascular Research Center; Fujian Medical University Heart Center, 350001 Fuzhou, Fujian, China

    4 shared publications
  • Lianglong Chen

    Department of Cardiology, Fujian Medical University Union Hospital, Fujian Institute of Coronary Heart Disease, Fuzhou, Fujian 350001, P.R. China

    3 shared publications
  • Hua Chen

    Department of Cardiology, Fujian Medical University Union Hospital, Fujian Cardiovascular Medical Center, Fujian Institute of Coronary Artery Disease, Fujian Cardiovascular Research Center

    2 shared publications
  • JinGuo Li

    Department of Cardiology, Fujian Medical University Union Hospital; Fujian Cardiovascular Medicine Center; Fujian Institute of Coronary Artery Disease; Fujian Cardiovascular Research Center; Fujian Medical University Heart Center, 350001 Fuzhou, Fujian, China

    2 shared publications
  • LingZhen Wu

    Department of Cardiology, Fujian Medical University Union Hospital; Fujian Cardiovascular Medical Center; Fujian Institute of Coronary Artery Disease; Fujian Cardiovascular Research Center, Fuzhou, PR China

    2 shared publications

Latest Publications

  • Open Access

    A small angle of shunting and detectable shunting inlet may predict successful exclusive transvenous closure of patent ductus arteriosus with a 3-year follow-up

    by Hui Ying Zheng, Dan Qing Hu, Wan Hua Chen, Hua Chen, Xiao Ping Yan, Jun Fang

    Background: The transvenous V-method simplifies transcatheter patent ductus arteriosus (PDA) closure compared with the arteriovenous (AV) method and retrograde transarterial coil occlusion, with fewer complications, but it carries variable failure rates. This study aimed to identify preoperative transthoracic echocardiography (TTE) predictors for V-method failure and establish a practical model to optimize procedural strategies. Methods: A total of 403 consecutive patients undergoing transcatheter PDA closure in Fujian Medical University Union Hospital between October 2014 and July 2019 were retrospectively enrolled and randomly split to training ( n = 282) and internal validation ( n = 121) cohorts at a 7:3 ratio. LASSO regression was performed to screen independent predictors. Model performance was validated via ROC, calibration and decision curve analysis. All patients received standardized 3-year postoperative follow-up. Results: Overall, 323 patients completed V-method closure, and 80 converted to the AV-method. The median age was 7 years (6 months-73 years) and an average PDA size of 4.43 mm (1.0mm–14.5 mm). Large shunt angle (defined as shunt beam–PDA inlet plane angle; A larger angle may indicate more perpendicular insertion to the pulmonary artery wall) and undetectable PDA shunting inlet on preoperative TTE were independent predictors of V-method failure. The dual-index model achieved excellent predictive performance with AUCs of 0.933 (training) and 0.910 (validation), along with favorable calibration and clinical net benefit. The optimal cut-off value for the model was defined as an undetectable PDA shunting inlet or a shunt angle > 81.61°, with a sensitivity of 89.5% and a specificity of 96.4%. At 3-year follow-up, no signal of excess harm was detected in either group. Conclusion: A small angle of shunting and detectable shunting inlet by echocardiography may predict successful exclusive transvenous PDA closure. The 3-year follow-up suggested the safety and efficacy of the exclusive transvenous access.

  • Open Access

    Ascending Aortic Diameter and Paravalvular Leak after Transfemoral Transcatheter Aortic Valve Replacement in Bicuspid and Tricuspid Aortic Valve Anatomy

    by Zilong Xie, Donghao Guo, Hengyi Zheng, Tinghui Xue, Jun Fang

    Background: Whether ascending aortic diameter is associated with perioperative paravalvular leak (PVL) differently in bicuspid (BAV) and tricuspid aortic valve (TAV) anatomy after transfemoral transcatheter aortic valve replacement (TF-TAVR) remains uncertain.Objectives: To evaluate the association between ascending aortic diameter and mild-or-greater perioperative PVL after TF-TAVR and assess whether it differs by valve morphology.Methods: This retrospective cohort included 212 patients with BAV or TAV who underwent TF-TAVR at Fujian Medical University Union Hospital from January 2021 to December 2025. The primary endpoint was echocardiographically assessed mild-or-greater perioperative PVL. Univariable and multivariable logistic regression were performed. Sensitivity analyses included complete-case analysis, alternative adjustment sets, extreme-value exclusion, winsorization, and Firth logistic regression.Results: Mild-or-greater PVL occurred in 119 patients (56.1%): 58 with BAV (54.2%) and 61 with TAV (58.1%). In fully adjusted models, the odds ratio per 1-mm increase in ascending aortic diameter was 1.123 in BAV (95% CI, 1.009–1.249; P=0.033), 0.996 in TAV (95% CI, 0.881–1.127; P=0.954), and 1.042 overall (95% CI, 0.972–1.117; P=0.243). Only the BAV association was significant. Sensitivity analyses yielded consistently positive estimates in BAV (OR range, 1.094–1.156).Conclusions: Larger ascending aortic diameter may be independently associated with mild-or-greater perioperative PVL in BAV after TF-TAVR. It may therefore contribute to BAV-specific CT risk assessment, although external validation is needed.Keywords: bicuspid aortic valve; transcatheter aortic valve replacement; paravalvular leak; ascending aorta; computed tomography

  • Open Access

    Long-term trends in the burden of non-rheumatic calcific aortic valve disease in China from 1990 to 2021, with projections to 2050: results from the global burden of disease study

    by Bin Jian, Zhen Li, Yu Huang, Zhixiong Wei, Gaoyang Zhao, Jun Fang

    Background: Non-rheumatic calcific aortic valve disease (NRCAVD) has emerged as a significant health challenge globally, with China’s rapidly aging population bearing a disproportionate burden, necessitating comprehensive epidemiological analysis to guide public health strategies. Methods: Utilizing data from the Global Burden of Disease (GBD) database 2021, we examined the incidence, prevalence, mortality, and disability-adjusted life years (DALYs), along with their corresponding age-standardized rates (ASRs), of NRCAVD in China from 1990 to 2021 and compared these data with global trends. The analysis employed joinpoint regression to calculate the estimated annual percentage change (EAPC) and average annual percentage change (AAPC) for evaluating NRCAVD trends over the past 32 years. Additionally, we employed the Bayesian age–period–cohort model to project these trends through 2050. Results: The age-standardized incidence and prevalence rates of NRCAVD in China increased from 1.42 to 2.52 per 100,000 and 17.24 to 32.68 per 100,000, respectively, between 1990 and 2021. Favorably, the age-standardized mortality and disability-adjusted life year rates of NRCAVD decreased from 0.10 to 0.07 per 100,000 and 2.42 to 1.92 per 100,000, respectively. The rates were higher in male individuals than in female individuals across all four metrics over the study period. In China, the estimated annual percentage changes for incidence, prevalence, mortality, and disability-adjusted life years were 2.04, 2.33, −1.34%, and −1.06%, respectively, while the average annual percentage changes for incidence, prevalence, mortality, and disability-adjusted life years were 0.04, 0.50, 0.00%, and −0.02%, respectively. The projections from Bayesian age–period–cohort model showed that the burden of NRCAVD is expected to continue through 2050. Conclusion: The burden of NRCAVD in China has dramatically increased from 1990 to 2021, with a notable rise associated with aging. Male individuals appear to be more susceptible than female individuals and face higher mortality risks associated with NRCAVD in China. The forecast suggests that this trend will persist until 2050, highlighting NRCAVD as a significant public health challenge in China over the next three decades.


  • Open Access

    Evolution of Clinical Features in Right Ventricular Outflow Tract Obstruction: Evidence From an Echocardiographic Database in China

    by LiYun Su, DanQing Hu, TingXiang Lan, Xiang Zhang, Shuang Liang, QianYao Lai, JinGuo Li, XuDong Sun, Jun Fang

    Background: Long-term right ventricular outflow tract dysfunction can lead to right and left heart failure. Nonetheless, current data on the clinical characteristics of the right ventricular outflow tract obstruction (RVOTO) in China remain limited. This study analyzed the evolving trends in the observed proportion, etiology, spectrum, and interventions for RVOTO over the past 18 years from a single-center echocardiographic database. Methods: A total of 10,234 RVOTO cases (17,451 records from 2003 to 2020) were included in the transthoracic echocardiography database in China. The RVOTO cases were divided into eight groups according to the different obstruction sites and disease types. Subsequently, RVOTO was categorized into three types: congenital, iatrogenic, and neither congenital nor iatrogenic. Moreover, congenital RVOTO was further classified into simple and complex congenital RVOTO. Next, we calculated the proportion of RVOTO patients who had received interventions. We analyzed the proportions of different types of RVOTO and the variation tendency. Results: During 2003–2008, 2009–2014, and 2015–2020, the observed proportion of RVOTO cases in the total echocardiographic cases decreased (3.2%, 2.1% and 1.8%, respectively; p < 0.001); the proportion of RVOTO with a congenital etiology also reduced, though as the dominant cause; meanwhile, the proportion of simple congenital RVOTO increased (48.5%, 52.4% and 67.3%, respectively; p < 0.001). As the two most common types of RVOTO, the proportion and number of valvular pulmonary stenosis (PS) increased, while the proportion of Fallot cases decreased. The number of RVOTO cases receiving surgical or transcatheter intervention and experiencing intervention-related severe pulmonary regurgitation (PR) or residual peripheral PS increased, although with a low probability of reoperation. Conclusions: The clinical characteristics of RVOTO have undergone significant changes in China over the past two decades. After the RVOTO intervention, the increasing number of cases with severe PR or residual peripheral PS and a low possibility of reoperation signifies a future necessity for transcatheter pulmonary intervention.


  • The passability of delivery catheter system during self-expanding transcatheter aortic valve replacement: A CT-based prediction model

    by Qianyao Lai, Zhixiong Wei, Xiang Zhang, Qianzhen Li, Shuang Liang, Liyun Su, Lianglong Chen, Jun Fang

  • Open Access

    Adropin inhibits the progression of atherosclerosis in ApoE-/-/Enho-/- mice by regulating endothelial-to-mesenchymal transition

    by Teng Ying, LingZhen Wu, TingXiang Lan, ZhiXiong Wei, DanQing Hu, YiLang Ke, Qiong Jiang, Jun Fang

    Adropin, a secreted protein, coded by energy homeostasis-associated gene (Enho), is recently reported to modulate atherogenesis, with endothelial-to-mesenchymal transition (EndMT) involved in the early process. We explored whether adropin may alleviate atherosclerosis by regulating EndMT. We found that an intraperitoneal injection of adropin [105 μg/(kg·d) for 13 weeks] inhibited the progression of high-fat diet (HFD)-induced aortic atherosclerosis in apolipoprotein E-deficient mice (ApoE–/–) and those with double gene deletion (ApoE–/–/Enho–/–), as detected by Oil Red O and haematoxylin-eosin staining. In the aortas of ApoE–/– mouse, adropin treatment ameliorated the decrease in the mRNA expression of endothelial cell markers (leukocyte differentiation antigen 31, CD31, and vascular endothelial cadherin, VE-cadherin), but increased that of EndMT markers (alpha smooth muscle actin, α-SMA, and fibroblasts specific protein-1). In vitro, an adropin treatment (30 ng/ml) arrested the hydrogen peroxide (H2O2)-induced EndMT in human umbilical vein endothelial cells (HUVECs), attenuated the morphological changes of HUVECs, reduced the number of immunofluorescence-positive α-SMA, increased the mRNA and protein expressions of CD31 and VE-cadherin, and decreased those of α-SMA. Furthermore, the adropin treatment decreased the mRNA and protein expressions of transforming growth factor (TGF)-β1 and TGF-β2, and suppressed the phosphorylation of downstream signal protein Smad2/3 in HUVECs. These mitigative effects of adropin on H2O2-induced EndMT were reversed by the transfection of TGF-β plasmid. The findings signify that adropin treatment may alleviate the atherosclerosis in ApoE–/–/Enho–/– mice by inhibiting EndMT via the TGF-β/Smad2/3 signaling pathway.


  • Open Access

    An 18-year evolution of congenital heart disease in China: An echocardiographic database-based study

    by DanQing Hu, TingXiang Lan, YiFan Chen, LinYan Chen, JinGuo Li, XuDong Sun, Hua Chen, Jun Fang


  • Open Access

    Adropin-based dual treatment enhances the therapeutic potential of mesenchymal stem cells in rat myocardial infarction

    by HuiYa Li, DanQing Hu, Guilin Chen, DeDong Zheng, ShuMei Li, YunLing Lin, HuaShan Hong, Yukun Luo, YiLang Ke, Yu Huang, et al.

    Both weak survival ability of stem cells and hostile microenvironment are dual dilemma for cell therapy. Adropin, a bioactive substance, has been demonstrated to be cytoprotective. We therefore hypothesized that adropin may produce dual protective effects on the therapeutic potential of stem cells in myocardial infarction by employing an adropin-based dual treatment of promoting stem cell survival in vitro and modifying microenvironment in vivo. In the current study, adropin (25 ng/ml) in vitro reduced hydrogen peroxide-induced apoptosis in rat bone marrow mesenchymal stem cells (MSCs) and improved MSCs survival with increased phosphorylation of Akt and extracellular regulated protein kinases (ERK) l/2. Adropin-induced cytoprotection was blocked by the inhibitors of Akt and ERK1/2. The left main coronary artery of rats was ligated for 3 or 28 days to induce myocardial infarction. Bromodeoxyuridine (BrdU)-labeled MSCs, which were in vitro pretreated with adropin, were in vivo intramyocardially injected after ischemia, following an intravenous injection of 0.2 mg/kg adropin (dual treatment). Compared with MSCs transplantation alone, the dual treatment with adropin reported a higher level of interleukin-10, a lower level of tumor necrosis factor-α and interleukin-1β in plasma at day 3, and higher left ventricular ejection fraction and expression of paracrine factors at day 28, with less myocardial fibrosis and higher capillary density, and produced more surviving BrdU-positive cells at day 3 and 28. In conclusion, our data evidence that adropin-based dual treatment may enhance the therapeutic potential of MSCs to repair myocardium through paracrine mechanism via the pro-survival pathways.


  • Open Access

    Adropin reduces hypoxia/reoxygenation‑induced myocardial injury via the reperfusion injury salvage kinase pathway

    by Lingzhen Wu, Jun Fang, Xun Yuan, Chang Xiong, Lianglong Chen

    Adropin is a secreted polypeptide that has been demonstrated to serve an important role in protecting the vascular endothelium. Pharmacological activation of pro‑survival kinases, such as PI3K‑Akt and ERK1/2, are involved in the reperfusion injury salvage kinase (RISK) pathway. In the present study, the effects of adropin in cardiomyocyte injury induced by simulated ischemia/reperfusion (SI/R) were assessed. Additionally, the current study also assessed the mechanisms that govern SI/R in a H9c2 cardiomyoblast cell model. Cell viability was measured using an MTT assay. Cell injury was assessed using creatine kinase MB measurements. Apoptosis was assessed using flow cytometry and caspase‑3 activity. The inflammatory response was measured using tumor necrosis factor α and interleukin‑10 expression. Oxidative stress was assessed using malondialdehyde and superoxide dismutase. The expression levels of Akt, ERK1/2, glycogen synthase kinase 3β (GSK3β), Bcl‑2 and Bax were determined using western blot analysis. The results of the current study revealed that moderate‑dose adropin increased cell viability, reduced early apoptosis and caspase‑3 activity, promoted Bcl‑2 expression, inhibited Bax and increased the Bcl‑2/Bax ratio. Adropin significantly increased the phosphorylation of Akt, ERK1/2 and GSK3β, whereas inhibitors of PI3K and ERK1/2, respectively, LY294002 and PD98059, abolished the cardioprotective role of adropin. Furthermore, no significant difference was observed in phosphorylated‑STAT3/total‑STAT3 expression between the adropin and SI/R groups and Janus kinase 2 inhibitor AG490 did not significantly inhibit the protective role of adropin. These results indicate that adropin exerts a protective effect against SI/R injury through the RISK pathway instead of the survivor activating factor enhancement pathway.


  • Pyrrolidine Dithiocarbamate Attenuates Cardiocyte Apoptosis and Ameliorates Heart Failure Following Coronary Microembolization in Rats

    by Shumei Li, Jun Fang, Lianglong Chen

    Background: Nuclear factor-kB is highly activated in cardiovascular disorders. However, few articles have targeted at the role of nuclear factor-kB inhibitor in heart failure. Aims: To evaluate the effects of nuclear factor-kB inhibitor pyrrolidine dithiocarbamate on cardiocyte apoptosis and cardiac function in a rat heart failure model. Study Design: Animal experiment Methods: A stable and reproducible rat heart failure model (n=64) was prepared by injecting homologous microthrombotic particles into the left ventricle of Sprague-Dawley rats while obstructing the ascending aorta to produce coronary microembolization. Rats with heart failure were randomized into untreated (HFu) and pyrrolidine dithiocarbamate-treated (HFp) groups; the latter received an intraperitoneal injection of pyrrolidine dithiocarbamate (100 mg/kg/day) 1 h prior to surgery as well as on postoperative days 1-7. The sham group comprised 32 Sprague-Dawley rats. Eight rats from each group were sacrificed on days 1, 3, 7, and 14 postoperatively. Masson's trichrome staining was used to determine the micro-fibrotic area to indicate the severity of myocardial loss. Terminal transferase uridine triphosphate nick end labeling staining was used to detect apoptotic cardiomyocytes. Echocardiography and hemodynamics were performed to evaluate left ventricular function. Results: Rats with heart failure exhibited pathological changes evidenced by patchy myocardial fibrosis, remarkably elevated severity of myocardial loss, and persistently reduced left ventricular function. At the end of the study, compared with the HFu group, myocardial infarct size was reduced by 28% (p= 0.001), cardiocyte apoptosis was suppressed (7.17%+/-.1.47% vs 2.83%+/- 0.75%, p<0.001), cardiac function parameters such as left ventricular ejection fraction (80%+/- 4% vs 61%+/- 6%), left ventricular + dP/dt max (4828 +/- 289 vs 2918 +/- 76 mmHg.s(-1)), left ventricular - dP/dt max (4398 +/- 269 vs 2481 +/- 365 mmHg.s(-1)), and left ventricular systolic pressure (126 +/- 13 vs 100 +/- 10 mmHg) were significantly increased, and left ventricular end-diastolic pressure was reduced (18 +/- 2 vs 13 +/- 1 mmHg) (p<0.001, for all) in the HFu group. Conclusion: Our rat model can adequately mimic heart failure via coronary vessel embolization. Moreover, pyrrolidine dithiocarbamate treatment can reduce cardiocyte apoptosis and improve cardiac function, which may be beneficial for patients with heart failure secondary to myocardial infarction.